Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Bactiguard, Audiocast, Q3'25

By Inderes10/23/2025, 9:00 AM
Bactiguard

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Operator
00:00 - 00:23

Welcome to the Bactiguard Q3 2025 report presentation. For the first part of the conference call, the participants will be in listen-only mode. During the question and answer session, participants are able to ask questions by dialing Pound Key five on their telephone keypad. Now I will hand the conference over to the speakers, CEO Christine Lind and CFO Patrick Bach. Please go ahead.

Christine Lind
00:26 - 15:59

Thank you. Operator, welcome to the presentation of Bactiguard's report for the third quarter of 2025. Our CFO, Patrick Bach, and I will go through the presentation together, and we will have a Q&A session towards the end. Let's start with some high-level comments on the quarter, and Patrick will go into more financial details later in the presentation. We have had another profitable quarter with EBITDA totaling 5.3 million SEK, and the investments we have made over the last two years in strengthening the organization and capabilities to support licensing have not jeopardized our margins or impacted profitability. Even though we do not yet demonstrate significant top-line growth, we deliver a strong EBITDA, and I am confident that we are equipped to execute on the opportunities for our infection prevention technology across our strategic therapeutic areas. Total revenues were just over 48 million, with licensing revenues of almost 30 million. Given our substantial US dollar exposure in the license business, the weaker US dollar continues to impact these revenues negatively. We also had an exceptionally strong third quarter in 2024, which set a high base for comparison. Notably, this quarter is the third strongest of the last ten quarters from the partnership, with only Q3 and Q4 of 2024 being stronger. We remain positive about the trajectory of in-market sales. Revenues from the Zimmer Biomet partnership were limited this quarter, as no milestone or minimum royalties were recognized during the quarter, as was expected. However, the partnership with Zimmer Biomet is progressing, including in the expansion of the clinical evidence supporting the advantages of the Bactiguard-coated trauma implants. Newly published clinical study data benefits not just the ZNN Bactiguard, but adds a robust body of clinical evidence for our coating technology that also supports our business development activities. Wound Management had a slower quarter compared to Q3 2024, with revenues of 15.6 million, but it is still expected to deliver double-digit growth. I will come back to more detail on each of these highlights later in the presentation. Before digging deeper into the third quarter, I would like to summarize why Bactiguard is a compelling investment opportunity beyond the fact that we are now a profitable business geared for growth. Firstly, there is a clear need for solutions to reduce the burden on patients, on healthcare practitioners, and in costs to the healthcare system from infections. Secondly, the Bactiguard coating technology and Hydrocyn aqua line of products are differentiated from other solutions, and the coating technology has multiple levels of validation from robust clinical studies, demonstrated manufacturing scalability, successful commercialization, and continued validation in real-world use over the last 30 years. Thirdly, our coating platform is highly scalable with proven compatibility on multiple types of materials and applicability to multiple therapeutic areas, including those that are as different from each other as urology, catheters, and orthopedic implants. Our licensing business model also means high leverage in Bactiguard's scale as our partners reach commercialization stages, and once our technology is embedded, it is integral to the device, making the revenue stream sticky and long-lasting. Fourthly, we build from a positive EBITDA base with new growth verticals and development, putting us at an inflection point for value creation on both sides of our business. I would also like to take a moment to reiterate our core value proposition. We provide global medtech companies with advanced technology that helps prevent medical device-related infections. Bactiguard technology is an ultra-thin coating of the noble metals gold, silver, and palladium that has been demonstrated to work on multiple types of materials and devices and in different clinical settings. We have, over time, coated more than 20 different materials with good outcomes, and more than 250 million devices have been coated for patient use. Our technology has amassed a wealth of evidence of its safety and efficacy in reducing medical device-related infections. Some 100,000 people have been part of clinical trials, demonstrating up to 70% infection rate reductions. And last, but certainly not least, in 30 years of real-world use, we have had zero adverse events related to the coating. In short, it's a track record that gives confidence to our licensed partners. For our licensing business, Bactiguard is focused on therapeutic areas where infection rates are relatively high and there is an urgent unmet medical need for effective infection prevention. Solution. Infection in these settings is linked to poor patient outcomes and, in severe cases, death, contributing to high healthcare costs and underscoring both the medical need and the market opportunity. Across these areas, there are clear applications suitable for our infection prevention technology and great potential to reduce medical device-related infections. These areas also represent the strongest potential for both enhanced and future licensing partnerships, combining high clinical evidence with tangible commercial potential for Bactiguard. Across the top of the partnership snapshot chart, our partnership stages outline the progress in our business development activities, matched against the relevant therapeutic area on the left. Starting from the top, we have our partnership in orthopedics within the trauma area with Zimmer Biomet at commercial stages in selected markets, and we have full rights available for licensing to all orthopedic applications. Outside of that, orthopedics represents a significant opportunity with an addressable market of nearly $40 billion. This area involves a high volume of procedures and consequently, a high incidence of device-related infections. We see significant opportunities moving forward in this segment. Cardiology is one of our newer strategic therapeutic areas and represents great potential for Bactiguard. With an addressable market of around $10 billion, cardiology includes a variety of implantable devices that are susceptible to infections, with reported infection rates of up to 7% for implantable electronic devices and up to 39% for ventricular assist devices. Despite a well-appreciated respect for infection prevention within the cardiology field, these infections pose major challenges, often leading to device failure that necessitates surgical intervention and places considerable strain on both patient recovery and healthcare resources. Last quarter, we initiated early feasibility work and are now progressing in non-clinical studies to demonstrate proof of concept in this area. In Urology, the Bactiguard-coated Foley catheter has already made a positive impact in preventing infections, especially in our long-standing partnership with Becton Dickinson. Urology continues to present strong growth potential both for the already partnered Foley catheter application area and for other applications within the field, including vascular access. We already have an evidence base from the previously approved and marketed BIP central venous catheter, which we are building on with additional non-clinical studies. Even though we are very excited about the variety of early-stage testing that is ongoing, bringing medtech innovations to market is a long-term process that can take several years from initial testing to commercialization. As mentioned in my CEO statement, the efforts we are making today and will continue to make in the coming quarters are building the foundation for future growth. We are steadfast in our strategic direction, targeting therapeutic areas with significant unmet medical needs, and forming partnerships where Bactiguard infection prevention technology delivers clear and lasting value. Now to give a bit more color on our commercial stage partnerships. As I noted earlier in Q3, the revenues from this partnership bounced back compared to the second quarter, and the momentum in our collaboration with global medtech company Becton Dickinson continues to be strong. Looking at the 2025 progress so far, the partnership has advanced steadily for their core US market. BD has introduced a dedicated product website with a comprehensive section offering evidence-based insights into how Bactiguard-coated catheters help reduce infections, improve outcomes, and strengthen prevention protocols. The Bactiguard-coated catheters were also launched in India, where healthcare-associated infections and antimicrobial resistance remain major challenges. The team has been actively working on transitioning this market, where we previously sold the Foley from Bactiguard to BD. Preparations for launch readiness in Europe are also ongoing, and we expect more market launches in the coming quarters. BD and Bactiguard continue to work closely together, sharing insights and jointly driving growth, and we remain fully aligned on growing the Bactiguard-coated Foley catheters business. Zimmer Biomet carries the Infection Solutions banner as high as we do, with this category being an important strategic pillar for them. Company-wide, the ZNN Bactiguard Trauma Nail system is part of the prevention focus area and continues to be commercially supported across Europe, including through Zimmer's exhibitions and educational symposia. At the annual meeting held in Barcelona this past September, multiple key strategic initiatives were discussed. Even though Q3 revenues from the Zimmer partnership were limited, we see in-market growth in sales of the ZNN Bactiguard orthopedic implants, and the partnership continues to make progress. Zimmer continues to work on increasing evidence supporting the Bactiguard technology through clinical studies with the ZNN Bactiguard trauma nail system in Europe. These studies are also part of the work towards transitioning to the MDR regulatory requirements for the CE mark in Europe, which continues according to plan. As a highlight for us this quarter through the Zimmer Biomet partnership, the publication of two independent studies in medical journals has further expanded the clinical evidence supporting the Bactiguard coated trauma. Now, the study conducted at the Leeds Major Trauma Centre in the UK is the first clinical comparative evaluation of noble metal alloy coated nails in a high-risk orthopedic trauma population. The aim. The aim of this pilot study was to assess the clinical effectiveness of two commercially available coated tibia nails compared with non-coated implants. The single-center cohort study included 234 patients over a ten-year period. All patients had tibial fractures considered at high risk of infection, and were treated with one of three types of implants. The coated trauma nail, ZNN Bactiguard, and antibiotic-releasing nail, or a standard uncoated tibial nail. The results showed that the Bactiguard coated nails had the lowest infection rate at 4.9%, compared to 7.8% for gentamicin coated nails and 13.2% for uncoated nails. Patients treated with Bactiguard coated implants also experienced fewer unplanned interventions due to complications, a lower nonunion rate, and no cases of anaerobic infections, which was a better outcome compared to both of the other treatment groups. While the study was not statistically powered for all outcomes, the data consistently confirm improved clinical results with Bactiguard coated nails. Another independent study recently published in the medical journal Injury was conducted at the Vall D'Hebron University Hospital in Barcelona, Spain. The objective of this study was to evaluate the clinical outcome of a novel hybrid bone transport technique, using a Bactiguard coated nail for the treatment of infected segmental tibial bone defects, and it showed good outcomes without increasing complications. These studies add to the growing body of evidence supporting Bactiguard's non-releasing biocompatible coating technology as a superior tool in the fight against implant-associated infections. I also just wanted to note that the Bactiguard technology was featured in a real emergency situation, captured in a Netflix documentary series covering the London trauma hospital system called Critical Between Life and Death, where a Bactiguard coated implant was used in a patient involved in a motorcycle and bus collision. While we expect to continue to see real patient outcomes published in medical journals, this unexpected but more accessible context was a gratifying recognition of Bactiguard's role in advancing infection prevention. The wound management portfolio had revenues of 15.6 million SEK, a decrease of 13% compared to Q3 last year, which was primarily related to a decline in suture sales. Hydrocyn aqua sales continued to expand, with growth delivered across all regions, and we continue to expect to deliver double-digit growth in wound management in line with our strategic targets. Our focus in the near term is on onboarding new distributors in multiple markets to support the clinically differentiated marketing and sales of the Hydrocyn aqua line of products, and capture the demand we see in wound cleansing and healing, as well as the future potential in surgical settings and peritoneal lavage. And now I will hand over to Patrick to review our Q3 financial outcomes in more detail.

Patrick Bach
16:02 - 23:14

Preparations for launch readiness in Europe are ongoing, and we expect more market launches in the coming quarters. With our release this morning, we, in short, delivered a continued positive EBITDA of 5.3 million in Q3 alone, despite a decrease in the total revenues across our business. Total revenue amounted to 48.4 million, down 25.5 million, or 35%, due to negative currency effects and a high comparison from the same quarter last year. Net sales amounted to 45.5 million, a decrease of 27%. Net of negative currency effects. This was driven by lower revenues in both our licensing business as well as within wound management this quarter. First, net of currency, we see 30% lower revenues in our license business, amounting to almost 30 million for Q3, again versus a high comparison of 46.6 million last year. This mainly pertains to periodic effects in semi revenues, where no minimum royalties were booked and the overall currency effects. Secondly, in our wound management portfolio, we saw a total decrease in revenues to 15.6 million, or about a 12% decrease net of currency effects. We do see continued growth for Hygrocyn aqua. As mentioned in the last quarter, this represents the majority of our business and revenues. However, we saw a decline in suture sales in Q3, impacting the total wound management result on a year-to-date basis. We now see the total wound management business growing at 8%, fueled by high double-digit growth in Hygrocyn aqua, and we remain confident and still expect our total wound management portfolio to deliver double-digit growth going forward. Finally, looking at the total revenues, as expected, we had no revenues recorded in Q3 and for the year-to-date period. This results in a negative top line effect of 12 million, reflecting the discontinued bid portfolio that is included obviously in our 2024 base. This results in a negative top line effect of 12 million, reflecting the discontinued Bid portfolio that is obviously included in our 2024 base. In addition, other revenues for the quarter were down 3.7 million. And year to date, other revenues are down 4.7 million, mainly driven by the negative currency effects. So naturally, this negatively impacts the total revenue comparison versus last year. Looking closer at our core licensed business, we saw Q3 licensed partner revenues of 29.8 million, a decrease of almost 17 million, or 29%, adjusted for the negative currency effects of more than 3 million. Despite the BD bounce back and recovery from last quarter, BD revenues came in at 28.3 million, down 15% versus the high quarter last year of more than 33 million. Here, we see negative currency effects alone of more than 3 million. And net of this, we see a 5% decrease versus the high comparison quarter last year. We remain confident in the strength and future growth of our BD partnership. Similarly, Q3 revenues amounted to 1.5 million. Obviously, a large decrease of more than 9 million. However, this is explained by the fact that no minimum royalties were booked this quarter. Yet, net of currency effects, there's merely a 5% decline against the high base comparison period. We remain confident in the positive in-market growth and positive demand from clinicians we see across our partnerships for our technology. On costs, we continue to make progress in reducing costs and complexity across our business. In Q3, our total operating costs decreased by 36% to 36.6 million, resulting in more than 20 million in net savings for the quarter alone. This decrease is mainly related to higher external costs in the corresponding quarter last year, which were driven by increasing costs for consulting, regulatory, and legal services in the first nine-month period. Our total operating expenses amounted to 119.9 million, a decrease of more than 33 million compared to the same period last year, corresponding to a 22% savings on a rolling 12-month basis. We now see operating expenses costs down at 174 million. As mentioned, despite a decline in revenues, we continue to deliver positive EBITDA with 5.3 million for Q3 alone, a slight improvement versus our Q2 result, but down versus our Q3 last year. Our rolling 12-month EBITDA this quarter is slightly down at 27.5 million. Finally, the Q3 operating loss amounted to 6.4 million, again a slight improvement compared to our Q2 last quarter, yet higher than Q3 last year. Net loss amounted to 7.5 million for Q3, and net loss for the period January to September amounted to 20.4 million, an improvement of 8.5 million versus last year's year-to-date period. In Q3. Our total cash flow for the period was -8.4 million, while cash flow from operating activities was -2.8 million. Looking at the nine-month period, the total negative cash flows mainly pertained to the voluntary amortization of 51 million in the refinancing earlier in the year, and year-to-date, cash flow from operating activities is -13.2 million. All in all, total cash at the end of Q3 is 37.4 million, net of repayments. With that, back to you, Christine.

Christine Lind
23:15 - 24:38

Thank you, Patrick. Time to conclude and share a few key takeaways. The positive profitability trend continued in Q3 despite a comparatively lower top line. Our existing partnerships continue to make progress both clinically and in preparation for future market launches. We continue to build the partnership pipeline through new business development efforts and early proof of concept studies, and our Wound Management business is expected to deliver double-digit growth driven by our flagship Hygrocyn aqua product line. I will leave you with this final slide outlining the strategic focus areas to meet our 2030 targets. We will remain focused on continuing to drive growth while maintaining discipline in our costs. We will continue to strengthen our existing partnerships and advance new opportunities and early-stage testing in our key strategic therapeutic areas. We will accomplish this through our knowledge and specialist expertise to be the very best partner to our partners. Together with our partners, we will reach more patients, prevent more infections, and achieve positive outcomes in both our coating technology and wound management portfolios. And with that, I would like to hand back to the operator to open up for questions.

Operator
24:39 - 24:56

If you wish to ask a question, please press the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Matthias Vanston from SIB. Please go ahead.

Matthias Vanston
24:58 - 25:01

Hello, Patrick and Christine. Can you hear me?

Christine Lind
25:02 - 25:03

We now see opex costs down at 174 million. Good morning. Matthias.

Patrick Bach
25:03 - 25:04

Morning, Matthias.

Matthias Vanston
25:05 - 25:36

Perfect. I have three questions. First one, you mentioned the report on market growth for ZNN Bactiguard. And the partnership is progressing on multiple fronts. Could you expand on this? Or if you can expand on this, and if there is anything that happened lately that we should be aware of, and also cover maybe what countries are selling the product today and where there is a sort of momentum building. That's the first question.

Christine Lind
25:38 - 26:53

Absolutely. Thank you. Great question. Regarding the in-market growth and where we see progress in the partnership. What we do note is that even though our partnership contract is structured around a global agreement with multiple prongs, Zimmer has launched primarily in the European markets. So this is broadly across Europe, including the UK, of course, where the studies were also delivered, and we see actual in-market product sales growth, which is very positive for us, even though our revenues from the partnership cover more areas than just in-market sales. So, Patrick can give you a little bit more detail on this as well. But that, of course, is a positive for us to actually see pull-through in the market of growth and demand for the ZNN Bactiguard product. As we noted, the product is widely available across Europe. It is in the major markets first, and Zimmer continues to work on increasing market expansions as well, even within the European countries. It's also available in Saudi Arabia and South Africa. But of course, those are smaller markets than the European markets put together.

Unknown 1
26:54 - 26:55

We can ask more about this topic.

Matthias Vanston
26:55 - 26:55

Perfect.

Patrick Bach
26:55 - 28:08

Just to add to Christine. Absolutely. We see positive in-market growth across both partnerships. For Zimmer, royalties in-market are growing from a low base but are increasing at a double-digit rate. And as Christine has mentioned, we've seen positive feedback across large markets. As we also mentioned, in this quarter alone, we did not book any minimum royalties. You may compare this quarter not with our Q2, last quarter, but rather with Q1 this year for BD as well. Despite that, we see a net of currency effects. decline this quarter of 5%. The year-to-date growth that we see in the market is positive. As we reported last quarter, we see mid-single-digit positive growth coming from existing BD markets. And as Christine Lind mentioned, we are also excited and expect more future launches in the coming quarters.

Matthias Vanston
28:10 - 28:29

Okay. That was actually touching on my next question regarding BD. It was, as you say, climbing back. So I guess communication will be more normalized going forward. And yes, there are certain arguments for growth to resume in 2026. All else equal.

Christine Lind
28:31 - 29:00

Yes, we continue to see BD making progress in their planning for new market launches, which we are, of course, working on together with them. And as I think we indicated last quarter, although the timelines are taking a bit longer for BD to receive the necessary market regulatory approvals to actually execute the launches. We do continue to make progress on the planning for those launches, and we're very confident about the periods ahead.

Matthias Vanston
29:03 - 29:21

Thank you. And then I have a question about the partner dialogues, collaboration work, and so on. If you could provide us with some insights on this, that would be great. How has it progressed here, maybe during Q3 or year to date?

Christine Lind
29:23 - 30:46

For sure. One of the things that we've continued to work on as Bactiguard has transitioned to a primarily partnership model in the license portfolio is to change from being a supplier of product or supplier of concentrate to our partner, to being a true partner. And that includes both in terms of how we work on data, non-clinical data to help support claims, continued market growth, and even for the commercialized products, all the way through helping them work together on Train the Trainer events that allow them to do sales launches in new markets. We appreciate that we are the experts on our coating and what it can deliver to patients and patient care, and we work actively together with our partners who have the underlying devices that also deliver benefits to patients to ensure that we have a joint message that works in the market. So it covers everything from work on the technology all the way through to the market launches and how the products are positioned. This definitely helps us align with our partners, where they carry similar messaging and appreciation for patient outcomes and impact on infection prevention as strongly as we do when they go to market with our products.

Matthias Vanston
30:49 - 30:50

Okay. Thank you very much.

Christine Lind
30:53 - 30:53

Thank you, Mathias.

Patrick Bach
30:54 - 30:54

Thank you, Mathias.

Operator
30:58 - 31:20

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Christine Lind
31:23 - 31:43

There appear to be no written questions, so I will conclude and thank everyone for joining us today on the call. Thank you for your questions and for listening in today, and we look forward to our next opportunity to engage with you. In the meantime, please do not hesitate to reach out. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…